Last reviewed · How we verify
Ami-LC
At a glance
| Generic name | Ami-LC |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PHASE1)
- Metabolic Characteristics of Type 2 Diabetes Mellitus Combined With Acute Myocardial Infarction: A Untargeted Metabolomics Study
- Metabolomics Profiling of Coronary Heart Disease
- Shotgun Mass Spectrometry-based Lipid Profiling in Chronic Inflammatory Diseases
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ami-LC CI brief — competitive landscape report
- Ami-LC updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI